Anne-Laure Brun

Dr. Anne-Laure Brun

Hôpital Foch, Radiology department, Suresnes, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Philippe A. GrenierPhilippe A. Grenier
Philippe A. Grenier
ABAnne-Laure Brun
Anne-Laure Brun
FMFRANCOIS MELLOT
FRANCOIS MELLOT
Two large randomized controlled trials of low-dose CT (LDCT)-based lung cancer screening (LCS) in high-risk smoker populations have shown a reduction in the number of lung cancer deaths in the screening group compared to a control group. Even if various countries are currently considering the implementation of LCS programs, recurring doubts and fears persist about the potentially high false positive rates, cost-effectiveness, and the availability of radiologists for scan interpretation. Artificial intelligence (AI) can potentially increase the efficiency of LCS. The objective of this article is to review the performances of AI algorithms developed for different tasks that make up the interpretation of LCS CT scans, and to estimate how these AI algorithms may be used as a second reader. Despite the reduction in lung cancer mortality due to LCS with LDCT, many smokers die of comorbid smoking-related diseases. The identification of CT features associated with these comorbidities could increase the value of screening with minimal impact on LCS programs. Because these smoking-related conditions are not systematically assessed in current LCS programs, AI can identify individuals with evidence of previously undiagnosed cardiovascular disease, emphysema or osteoporosis and offer an opportunity for treatment and prevention.

30 April 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
ABAnne-Laure Brun
Anne-Laure Brun
MCMarie-Laure Chabi
Marie-Laure Chabi
CPClément Picard
Clément Picard
FMFRANCOIS MELLOT
FRANCOIS MELLOT
Philippe A. GrenierPhilippe A. Grenier
Philippe A. Grenier
Chronic lung allograft rejection remains one of the major causes of morbi-mortality after lung transplantation. The term Chronic Lung Allograft Dysfunction (CLAD) has been proposed to describe the different processes that lead to a significant and persistent deterioration in lung function without identifiable causes. The two main phenotypes of CLAD are Bronchiolitis Obliterans Syndrome (BOS) and Restrictive Allograft Syndrome (RAS), each of them characterized by particular functional and imaging features. These entities can be associated (mixed phenotype) or switched from one to the other. If CLAD remains a clinical diagnosis based on spirometry, computed tomography (CT) scan plays an important role in the diagnosis and follow-up of CLAD patients, to exclude identifiable causes of functional decline when CLAD is first suspected, to detect early abnormalities that can precede the diagnosis of CLAD (particularly RAS), to differentiate between the obstructive and restrictive phenotypes, and to detect exacerbations and evolution from one phenotype to the other. Recognition of early signs of rejection is crucial for better understanding of physiopathologic pathways and optimal management of patients.

17 January 2024 in European Journal of Radiology
Verified
Journal Article
Closed access
AVAlexandre Vallée
Alexandre Vallée
RQRaphaelle Quint
Raphaelle Quint
ABAnne-Laure Brun
Anne-Laure Brun
FMFrançois Mellot
François Mellot
Philippe A. GrenierPhilippe A. Grenier
Philippe A. Grenier

14 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
MCMarie-Laure Chabi
Marie-Laure Chabi
ODOphelie Dana
Ophelie Dana
TKTitouan Kennel
Titouan Kennel
AGAlexia Gence-Breney
Alexia Gence-Breney
HSHélène Salvator
Hélène Salvator
Philippe A. GrenierPhilippe A. Grenier
Philippe A. Grenier
The purpose of our work was to assess the independent and incremental value of AI-derived quantitative determination of lung lesions extent on initial CT scan for the prediction of clinical deterioration or death in patients hospitalized with COVID-19 pneumonia. 323 consecutive patients (mean age 65 ± 15 years, 192 men), with laboratory-confirmed COVID-19 and an abnormal chest CT scan, were admitted to the hospital between March and December 2020. The extent of consolidation and all lung opacities were quantified on an initial CT scan using a 3D automatic AI-based software. The outcome was known for all these patients. 85 (26.3%) patients died or experienced clinical deterioration, defined as intensive care unit admission. In multivariate regression based on clinical, biological and CT parameters, the extent of all opacities, and extent of consolidation were independent predictors of adverse outcomes, as were diabetes, heart disease, C-reactive protein, and neutrophils/lymphocytes ratio. The association of CT-derived measures with clinical and biological parameters significantly improved the risk prediction (p = 0.049). Automated quantification of lung disease at CT in COVID-19 pneumonia is useful to predict clinical deterioration or in-hospital death. Its combination with clinical and biological data improves risk prediction.

24 July 2025 in Revue des Maladies Respiratoires
Verified
Journal Article
Closed access
ABAnne-Laure Brun
Anne-Laure Brun
BGB. Ghaye
B. Ghaye

28 May 2025
Verified
Book Chapter
Closed access
PDF file
ABAnne-Laure Brun
Anne-Laure Brun
PBP. Y. Brillet
P. Y. Brillet